An analysis of pan-cancer mutational data indicated a preponderance of stop codon mutations in the 5′ end of the SNF2 and helicase chromatin-remodelling domains of ATRX (in particular, R1426*) (Extended Data Fig. 1g). This evidence concerns the gene ATRX and cancer.